Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Impact of TP53 mutation on CD19-chimeric antigen receptor T-cell therapy in large B-cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

LSLingshuang ShengRSRong ShenZYZi‐Xun Yan

Discussion

Loading...

Member takes

Overview

Observational analysis shows TP53 mutation status does not significantly impact outcomes in R/R LBCL patients receiving CD19-CAR-T therapy, implying further studies are needed.

Key Points

  • TP53 mutation status did not significantly affect progression-free survival outcomes in large B-cell lymphoma patients receiving therapy.
  • Median progression-free survival was 41.1 months in TP53 mutation group versus not reached in TP53 wild type, with p=0.36.
  • Next-generation sequencing detected genomic alterations, aiding evaluation of therapeutic impact based on TP53 mutation status.
  • Further prospective studies are warranted to fully understand the implications of TP53 genomic alteration in CAR-T therapy.

Cite This Study

Sheng et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e44dhttps://doi.org/10.1182/blood-2025-1746
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Impact of TP53 mutations on survival outcomes in the CAR-t era of large b-cell lymphoma2025 · 1 citations
  2. 2Long-term follow-up reveals sustained benefit of dual CD19/CD22 CAR T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma2025
  3. 3Outcomes of Wild Type and TP53-Mutated B Cell Malignancy Patients Receiving CAR-T Cell Therapy: A Systematic Review and Meta-Analysis.2025 · 2 citations
  4. 4CAR-t cell therapy in TP53-mutated CNS lymphoma: Overcoming a high-risk genetic barrier2025
  5. 5Impact of germline and somatic TP53 mutations on allogeneic HSCT outcomes in hematologic malignancies2025